Angle's Parsortix Able To Predict Patients' Response To Treatment
Angle's Parsortix Able To Predict Patients' Response To Treatment
Read moreMon, 25th Feb 2019 10:51
Angle's Parsortix Able To Predict Patients' Response To Treatment
Read moreIN BRIEF: Angle Notes Study Showing "Key Capabilities" Of Parsortix
Read more(Sharecast News) - Angle announced on Monday that the University of Southern California (USC) has published peer-reviewed results of new work undertaken in metastatic breast cancer (MBC), highlighting advantages of a 'Parsortix' liquid biopsy, compared to standard-of-care tissue biopsy.
Read moreAngle Progresses On Parsortix And De Novo Clearance From US Regulator
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreIN BRIEF: Haydale Graphene Appoints Former AIM Market COO To Board
Read moreAngle's Parsortix Could Be Used To Pick MET Inhibitor Trial Subjects
Read more(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that the liquid biopsy analysis unit at the Health Research Institute of Santiago in Spain has published results of new work undertaken in head and neck cancer and non small cell lung cancer, on the potential utility of a liquid biopsy-based strategy to assess MET alterations on circulating tumour cells (CTCs).
Read moreUK TRADING UPDATE SUMMARY: Zenith Latest To Join Global Drive For PPE
Read more(Sharecast News) - Biopharmaceuticals group Angle said on Tuesday that progress had been impeded by the Covid-19 outbreak as the firm worked with a research and development skeleton crew in Guildford.
Read moreUK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial
Read more(Sharecast News) - Liquid biopsy company Angle said on Tuesday that operations in the UK, US and Canada had all been "severely disrupted" by the Covid-19 pandemic.
Read moreAngle Parsortix Test Used To Help Discover Brain Metastasis
Read moreAngle's Parsortix Beats Others In Assessing Kidney Cancer Patients
Read more(Sharecast News) - Liquid biopsy company Angle announced on Thursday that Istituto Nazionale Tumori di Milano in Milan, Italy, has published results of work assessing the performance of its 'Parsortix' system in renal cell carcinoma (RCC), demonstrating key advantages of Parsortix.
Read more